CL2011000099A1 - Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria. - Google Patents

Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.

Info

Publication number
CL2011000099A1
CL2011000099A1 CL2011000099A CL2011000099A CL2011000099A1 CL 2011000099 A1 CL2011000099 A1 CL 2011000099A1 CL 2011000099 A CL2011000099 A CL 2011000099A CL 2011000099 A CL2011000099 A CL 2011000099A CL 2011000099 A1 CL2011000099 A1 CL 2011000099A1
Authority
CL
Chile
Prior art keywords
defensin
medication
manufacture
treatment
inflammatory bowel
Prior art date
Application number
CL2011000099A
Other languages
English (en)
Spanish (es)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holsebrinch Karoline Sidelmann Mygind
Soeren Kjaserulff
Birg Andersen
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of CL2011000099A1 publication Critical patent/CL2011000099A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2011000099A 2008-07-18 2011-01-17 Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria. CL2011000099A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03

Publications (1)

Publication Number Publication Date
CL2011000099A1 true CL2011000099A1 (es) 2011-10-07

Family

ID=41530820

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000099A CL2011000099A1 (es) 2008-07-18 2011-01-17 Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.

Country Status (20)

Country Link
US (4) US8232242B2 (OSRAM)
EP (2) EP2399600A1 (OSRAM)
JP (2) JP2011528333A (OSRAM)
KR (1) KR20110092325A (OSRAM)
CN (2) CN102159233A (OSRAM)
AP (2) AP2011005538A0 (OSRAM)
AR (2) AR072032A1 (OSRAM)
AU (1) AU2009272681A1 (OSRAM)
BR (2) BRPI0915973A2 (OSRAM)
CA (2) CA2750727A1 (OSRAM)
CL (1) CL2011000099A1 (OSRAM)
EA (2) EA201100910A1 (OSRAM)
IL (2) IL210715A0 (OSRAM)
MX (1) MX2011000568A (OSRAM)
NZ (2) NZ593653A (OSRAM)
PH (1) PH12012501542A1 (OSRAM)
SG (1) SG172709A1 (OSRAM)
TW (2) TW201138810A (OSRAM)
WO (1) WO2010007166A2 (OSRAM)
ZA (1) ZA201100461B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110031962A (ko) * 2008-07-18 2011-03-29 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증 질환의 치료
CA2730666A1 (en) * 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
EP2399600A1 (en) 2008-07-18 2011-12-28 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
KR101329774B1 (ko) * 2010-06-16 2013-11-15 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
EP3448409B1 (en) * 2016-04-29 2025-12-03 Defensin Therapeutics ApS Treatment of liver, biliary tract and pancreatic disorders with defensins
AU2017376400A1 (en) 2016-12-13 2019-06-20 Novozymes A/S Methods for treating inflammatory conditions of the lungs
AU2018363783A1 (en) * 2017-11-10 2020-05-28 Novozymes A/S Maturation of mucosal defense and gut/lung function in the preterm infant
CN111741762A (zh) 2017-11-24 2020-10-02 防御素治疗学公司 使用防御素预防和治疗移植物抗宿主病
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用
WO2024225153A1 (ja) * 2023-04-27 2024-10-31 サントリーホールディングス株式会社 免疫活性化用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
NZ540506A (en) 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US8895062B2 (en) 2006-01-24 2014-11-25 University Of Maryland, Baltimore Surface-layer protein coated microspheres and uses thereof
RU2010113968A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида в качестве терапевтического средства
EP2399600A1 (en) 2008-07-18 2011-12-28 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
CA2730666A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
KR20110031962A (ko) 2008-07-18 2011-03-29 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증 질환의 치료
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide

Also Published As

Publication number Publication date
IL213680A0 (en) 2011-07-31
AR072032A1 (es) 2010-07-28
PH12012501542A1 (en) 2015-11-09
MX2011000568A (es) 2011-02-23
CA2730789A1 (en) 2010-01-21
AP2011005538A0 (en) 2011-02-28
AR081948A2 (es) 2012-10-31
US8802621B2 (en) 2014-08-12
WO2010007166A2 (en) 2010-01-21
JP2011528333A (ja) 2011-11-17
IL210715A0 (en) 2011-03-31
TW201138810A (en) 2011-11-16
SG172709A1 (en) 2011-07-28
WO2010007166A3 (en) 2010-06-03
US20110251139A1 (en) 2011-10-13
CN102247591A (zh) 2011-11-23
US20120309678A1 (en) 2012-12-06
US9279010B2 (en) 2016-03-08
BRPI0915973A2 (pt) 2013-05-07
ZA201100461B (en) 2014-03-26
EP2399600A1 (en) 2011-12-28
EA201170219A1 (ru) 2011-08-30
CN102159233A (zh) 2011-08-17
US8232242B2 (en) 2012-07-31
JP2011225596A (ja) 2011-11-10
TW201004640A (en) 2010-02-01
AP2011005755A0 (en) 2011-06-30
BRPI0924481A2 (pt) 2015-08-11
EP2320930A2 (en) 2011-05-18
AU2009272681A1 (en) 2010-01-21
CA2750727A1 (en) 2010-01-21
NZ593653A (en) 2012-09-28
US20100016230A1 (en) 2010-01-21
NZ590468A (en) 2012-06-29
EA201100910A1 (ru) 2012-05-30
US20140135258A1 (en) 2014-05-15
KR20110092325A (ko) 2011-08-17

Similar Documents

Publication Publication Date Title
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CO6410314A2 (es) Proteínas de unión a il-17
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CR20110262A (es) Materiales para crepar solubles en agua
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CO6321268A2 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
NI201000096A (es) TRATAMIENTO DE CARDIOPATÍAS USANDO Beta-BLOQUEANTES.
CL2008001766A1 (es) Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis.